{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Overall Response Rate= Minor response (\\>25%-50% reduction in serum IgM from baseline) + Partial Response (\\>50-90% reduction in serum IgM from baseline) + Very Good Partial Response (\\>90% reduction in serum IgM from baseline) + Complete Response (resolution of all symptoms, normalization of serum IgM with disappearance of IgM paraprotein, resolution of any adenopathy or splenomegaly).","groups":[{"description":"ABT199 will be administered daily, with 28 consecutive days defined as a treatment cycle for a maximum for 26 cycles\n\nABT199: Oral BCL-2 antagonist","id":"OG000","title":"ABT199"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"1 participant was censored from the response analysis after it was determined that he had IgM Myeloma rather than Waldenstrom's macroglobulinemia.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Overall Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}